Cargando…
SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
BACKGROUND: Obesity confers an increased risk and accelerates the progression of multiple tumor types in rodents and humans, including both breast and colon cancer. Because sustained weight loss is rarely achieved, therapeutic approaches to slow or prevent obesity-associated cancer development have...
Autores principales: | Nasiri, Ali R., Rodrigues, Marcos R., Li, Zongyu, Leitner, Brooks P., Perry, Rachel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907191/ https://www.ncbi.nlm.nih.gov/pubmed/31867105 http://dx.doi.org/10.1186/s40170-019-0203-1 |
Ejemplares similares
-
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors
por: Kellon, Eleanor M., et al.
Publicado: (2023) -
Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
por: Kellon, Eleanor M., et al.
Publicado: (2022) -
SUN-672 SGLT2 Inhibitor Reduces Hyperinsulinemia and Restores Pulsatile Growth Hormone Secretion in Obese MC4RKO Mice
por: Huang, Zhengxiang, et al.
Publicado: (2020) -
Hyperinsulinemia Associated Depression
por: Sarwar, Haider, et al.
Publicado: (2022) -
Mice endometrium receptivity in early pregnancy is impaired by maternal hyperinsulinemia
por: Li, Runqin, et al.
Publicado: (2017)